DUO-O : A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

Female<br/>OnlyGender Female
Only

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18-150Age 18-150

Female Reproductive<br/>System CancersCancer LocationFemale Reproductive
System Cancers

Systemic therapy,Treatment | Female reproductive organsEndometrium,Fallopian tube,Ovary,Peritoneal

Trial Overview Read MoreRead more

This phase III trial is evaluating the safety and effectiveness of various targeted therapy and chemotherapy combinations for the treatment of newly diagnosed, advanced ovarian cancer.
 

This trial is treating patients with ovarian cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

Commercial Sponsor

AstraZeneca

Summary

Eligible patients will be randomised to one of three trial Arms. In Arm 1: patients will receive platinum-based chemotherapy in combination with bevacizumab and a durvalumab placebo (saline IV infusion) followed by maintenance bevacizumab, a durvalumab placebo (saline IV infusion) and an olaparib placebo (tablets). In Arm 2: patients will receive chemotherapy in combination with bevacizumab and durvalumab, followed by maintenance bevacizumab, durvalumab and an olaparib placebo. In Arm 3: patients will receive chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib. In Arm 4: patients will also receive chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib, however in this arm bevacizumab will be optional according to local practice.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Enquiries Line Coordinator
clinicaltrials.enquiries@petermac.org
03 8559 7456 (9am-2pm, Mon-Fri)

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next